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Abstract
Background: Allogeneic hematopoietic stem cell transplantation and checkpoint blockade therapy are immune-
based therapies that have activity in selected refractory hematologic malignancies. Interest has developed in
combining these treatments for high-risk hematologic diseases. However, there is concern that checkpoint
blockade could augment graft-versus-host disease, and very few studies have evaluated the safety of checkpoint
blockade in the post-allogeneic setting. Here, we report the outcomes of three patients with relapsed classical
Hodgkin’s lymphoma following allogeneic transplant that were treated with the anti-PD-1 antibody, nivolumab.
Case presentations: Three patients with Hodgkin’s lymphoma relapsed following allogeneic transplant received
nivolumab therapy at our institution. All patients were free of graft-versus-host disease and were off of all systemic
immunosuppressive medications at the time of nivolumab treatment. Nivolumab was well-tolerated in two of the
patients. However, nivolumab had to be discontinued in one patient due to development of immune-related
polyarthritis requiring treatment with systemic corticosteroids and methotrexate. Objective responses were
observed in all three patients.
Conclusions: Our case series demonstrates that anti-PD-1 therapy with nivolumab can be highly effective following
allogeneic transplant for Hodgkin’s lymphoma, but serious immune-related adverse events can occur, requiring very
close monitoring and interruption of therapy.
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Background
Allogeneic hematopoietic stem cell transplantation
(alloHSCT) can be a curative treatment for high-risk
and recurrent hematological malignancies [1]. A major
therapeutic effect of alloHSCT lies within the graft-
versus-tumor (GVT) response, where donor-derived
lymphocytes recognize antigens expressed on the surface
of malignant cells, and eliminate them from the host [2].
However, it has become clear that disease relapse follow-
ing alloHSCT can be associated with immune evasion
and loss of GVT effects [3]. Concrete examples include
upregulation of programmed death-ligand 1 (PD-L1) on
leukemia cells, and programmed death-1 (PD-1) on
donor-derived T cells at the time of post-alloHSCT re-
lapse, as well as deletion of human leukocyte antigen al-
leles in some leukemia patients relapsing after
haploidentical alloHSCT [4, 5]. New strategies to restore
GVT effects in these patients are needed because pa-
tients who relapse after alloHSCT have few treatment
options and dismal outcomes [6].
Recently, the defined activity of checkpoint blockade
therapy (CBT) with anti-PD-1 and anti-cytotoxic
lymphocyte antigen-4 (CTLA-4) antibodies in a number
of malignancies has generated interest in their use to
treat disease relapse following alloHSCT. Preclinical
studies of CBT have demonstrated augmentation of
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GVT effects [7–9], and two phase I studies of the anti-
CTLA-4 antibody, ipilimumab, have been reported in
patients with relapse after alloHSCT, where objective re-
sponses were observed [10, 11]. In the most recently
published study, ipilimumab treatment was associated
with a 31% objective response rate, including complete
responses in patients with leukemia cutis, myeloid sar-
coma, and myelodysplastic syndrome [11].
However, there is concern that enhancing the GVT ef-
fect through administration of CBT might also induce or
exacerbate graft-versus-host disease (GVHD). Indeed,
ipilimumab treatment was discontinued in 4 of 29 pa-
tients due to GVHD in the aforementioned study, and 6
patients had other immune-related adverse advents
(IrAE) including one treatment-related death [11]. Fur-
ther, PD-1 blockade has also been associated with induc-
tion of severe GVHD in murine models, and a report of
fatal GVHD in a patient treated with the anti-PD-1 anti-
body, pembrolizumab, was recently published [12, 13].
These observations have somewhat tempered enthusi-
asm for the exploration of PD-1 blockade after
alloHSCT to anecdotal reports and a retrospective case
series which has been published in abstract form [14–
16]. However, PD-1 blockade has been associated with a
lower incidence of severe IrAE in non-transplant settings
compared to CTLA-4 blockade, and is clearly more ef-
fective across a number of malignancies, including clas-
sical Hodgkin lymphoma (cHL) [17, 18]. We therefore
sought to examine the safety and efficacy of PD-1 block-
ade following alloHSCT, and present data summarizing
our experience with nivolumab for the treatment of re-
lapsed cHL after alloHSCT.
Case presentation
We treated three cHL patients who had relapsed after
alloHSCT with off-label nivolumab at a dose of 3 mg/kg
every 2 weeks. Patient and disease characteristics are
summarized in Table 1. Briefly, all patients had multiply
relapsed cHL despite treatment with conventional
chemotherapy regimens and autologous hematopoietic
stem cell transplantation. Patients received T cell-
depleted grafts after reduced-intensity conditioning regi-
mens. None developed acute GVHD, although two pa-
tients developed limited-stage chronic GVHD requiring
short courses of steroids. Disease relapse occurred at an
average of 1,008 days from alloHSCT (181, 389, and
2456 days), and was histologically confirmed in all cases.
One patient received a donor lymphocyte infusion (DLI)
at the time of relapse, but failed to achieve an objective
response. After exhausting all conventional treatment
options, patients were consented to treatment with nivo-
lumab after discussing potential risks including life-
threatening GVHD.
All three patients had no clinical evidence of acute or
chronic GVHD at the time of initiating nivolumab, and
immunosuppressive medications had been discontinued
at least a year prior to starting therapy. Observed nivolu-
mab IrAE are listed in Table 1, and included grade 2
keratoconjunctivits in 2 patients, responsive to cortico-
steroid eye drops in both, grade 1 rash (possibly
Table 1 Patient characteristics, adverse events, and response to nivolumab treatment
Patient 1 Patient 2 Patient 3
Age 47 25 55
Sex Male Male Male
Prior therapies (no.) 6 6 5
Stem cell source Matched-related Matched-related Haploidentical and umbilical cord blood
Conditioning regimen Reduced intensity Reduced intensity Reduced intensity
T cell depleted graft Yes Yes Yes
Prior GVHD No Chronic GVHD of gut Chronic oral GVHD
Days to relapse following AlloHSCT
(no.)
181 2456 389
Localization and size of relapse Diffuse bone and splenic
involvement
Multifocal adenopathy in mediastinum,
retroperitoneum and pelvis. Largest
lymph node 2.3 × 1.5 cm in
mediastinum
Multifocal adenopathy in neck, chest,
abdomen and pelvis. Largest lymph
node 4.2 × 1.8 cm in right axilla
Prior DLI No Yes No
Immune-related adverse events Grade 2 Keratoconjunctivitis Grade 3 Inflammatory polyarthritis and
grade 2 keratoconjunctivitis
Grade 1 Rash
Response to nivolumab Partial response Partial response Partial response
Duration of response 6 Months+ 10 Months+ 14 Months+
Donor CD3+ chimerism before and
after treatment
18 to 49% Not available Not available
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representing limited-stage chronic GVHD) in 1 patient,
successfully treated with topical steroids, and one grade
3 episode of inflammatory polyarthritis, that required
treatment discontinuation and administration of sys-
temic corticosteroids and methotrexate to control. Mean
duration of therapy is 8.3 months and is continuing in
two patients. All patients had objective partial responses
to treatment based on the results of interim PET scans
(Fig. 1a). Responses are ongoing in all patients at the
time of publication. In addition to radiographic re-
sponses, one patient with severe pancytopenia due to
marrow involvement by cHL achieved a marked im-
provement in peripheral blood counts, as well as an ob-
jective improvement in bone marrow involvement by
cHL (Fig. 1b). Immunohistochemistry studies on bone
marrow biopsy samples before and after 5 cycles of nivo-
lumab therapy in this patient demonstrated abundant
PD-L1 expression in Hodgkin cells, with an increase in
tumor-infiltrating CD8+ T cells and decreased CD4+ T
cells with therapy (Fig. 2). Furthermore, bone marrow
chimerism studies demonstrated an increase in the
donor CD3+ compartment from 18 to 49% with
treatment.
Discussion and Conclusions
Our data conclusively demonstrate that anti-PD-1 therapy
with nivolumab is effective for relapsed cHL following
alloHSCT. All three patients have achieved objective and
ongoing responses to treatment. These findings are con-
sistent with previous observations demonstrating immune
escape as a mechanism of relapse following alloHSCT,
and that immune activating therapies such as DLI and
CBT have the potential to restore GVT effects [3–5, 7–11,
19]. The finding of an objective response in a patient
Fig. 1 Radiographic and hematologic responses with therapy. a Response as assessed by sequential PET scan images. Images are shown for
Patients 2 and 3. The response for Patient 1 was more difficult to illustrate on PET scan as his disease was primarily confined to the bone marrow.
b Serial complete blood counts during treatment with nivolumab demonstrating significant tri-lineage improvement for Patient 1. *Platelet units
(×10^3/uL) are provided on the left y-axis, while hemoglobin (g/dL) and white blood cell count units (×10^3/uL) are on the right y-axis
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Fig. 2 (See legend on next page.)
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refractory to DLI, also demonstrates that PD-1 blockade
reinvigorates GVT responses through distinct pathways
that potentially more effectively activate GVT effects.
The toxicity of PD-1 blockade following alloHSCT will
be an important measure to continue to assess in pro-
spective studies. We did not observe any GVHD; how-
ever, several IrAEs occurred among the three patients
reported here, none of which was life-threatening. It is
expected, as has recently been reported [13], that the
use of anti-PD-1 antibodies may result in severe
immune-related toxicities in the post-allo-HSCT setting.
While our results are encouraging, it is not known
whether other hematologic cancers will also be respon-
sive to PD-1 blockade in the post-alloHSCT setting. That
being said, complete responses to ipilimumab were ob-
served after alloHSCT in patients with relapsed leukemia
cutis and myelodysplastic syndrome [11]. This is an im-
portant observation since single-agent ipilimumab has
only modest activity in hematologic malignancies outside
of the alloHSCT setting [20], and may indicate that CBT
and alloHSCT have therapeutically synergistic effects. In
support of this, our finding of increased donor CD3+
chimerism at the site of disease involvement in one of
our patients, suggests that anti-tumor effects are prefer-
entially driven by donor-derived T cells following PD-1
blockade. Biologically, the enhanced activity of combin-
ing CBT with alloHSCT could be related to the observa-
tion that immune responses generated by PD-1 blockade
are likely restricted to tumor neo-antigens in the non-
transplanted host [21], whereas immune responses from
donor-derived T cells are targeted against minor histo-
compatibility antigens that are more uniformly
expressed [22]. Furthermore, anti-PD-1 antibodies may
enhance the efficacy of alloHSCT by reinvigorating the
GVT effect in hematological cancers that acquire PD-L1
expression as an adaptive response to immune pressure.
Therefore the complementary immune effects of
alloHSCT and PD-1 blockade hold promise in both the
prevention and treatment of relapse following alloHSCT.
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